21 Oct 2021
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
Author: admintech | Filed under: Press ReleaseCAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ — Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1 study evaluating its investigational agent…